Details of Drug-Drug Interaction
| Drug General Information (ID: DDI3R4IUO8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Mephentermine | Drug Info | Milnacipran | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Vasoconstrictor Agents | Antidepressants | |||||||
| Structure | |||||||||
| Mechanism of Mephentermine-Milnacipran Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypertensive effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Mephentermine | Milnacipran | |||||||
| Mechanism 1 | Hypertensive effects | Hypertensive effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypertensive effects | ||||||||
| Factor Description | Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head. | ||||||||
| Mechanism Description |
|
||||||||
| Increased risk of rapid heart rate Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Mephentermine | Milnacipran | |||||||
| Mechanism 2 | Increased heart rate | Increased heart rate | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Tachycardia | ||||||||
| Factor Description | A faster-than-normal heart rate, but the heart is beating normally. Tachycardia may not cause any symptoms or complications, but if left untreated, some forms of tachycardia can lead to serious health problems, including heart failure, stroke, or sudden cardiac death. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate. | ||||||||